Tarvainen T, et al. - Researchers examined the effectiveness of hydrocortisone vs pasireotide in reducing complications after partial pancreatectomy. They conducted a noninferiority, parallel-group, individually randomized clinical trial including 126 patients who were undergoing partial pancreatectomy. Participants were randomized to receive treatment including pasireotide, 900 μg, subcutaneously twice a day for 7 days or hydrocortisone, 100 mg, intravenously 3 times a day for 3 days. Patients receiving pasireotide reported –6.16 points lower mean Comprehensive Complication Index score (a measurement of overall postoperative morbidity). In subgroup analyses of patients undergoing distal pancreatectomy, significantly lower (10.3 points) mean Comprehensive Complication Index score was reported in the pasireotide vs hydrocortisone group. These findings suggest hydrocortisone as not noninferior vs pasireotide. Possibly, pasireotide is more effective in lowering postoperative complications in patients undergoing distal pancreatectomy.